Exact Sciences (NASDAQ:EXAS) Issues Earnings Results

Exact Sciences (NASDAQ:EXAS) posted its earnings results on Wednesday. The medical research company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23, Zacks reports. The company had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 37.29%. Exact Sciences updated its FY 2025 guidance to EPS.

Exact Sciences Stock Performance

Shares of NASDAQ EXAS traded up $0.01 during trading hours on Friday, reaching $49.52. The stock had a trading volume of 671,244 shares, compared to its average volume of 2,257,608. The firm has a market cap of $9.16 billion, a price-to-earnings ratio of -8.89 and a beta of 1.24. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. Exact Sciences has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The firm has a 50-day moving average of $55.15 and a 200-day moving average of $60.03.

Analyst Ratings Changes

Several research firms recently issued reports on EXAS. Citigroup cut their price objective on Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. BTIG Research boosted their price objective on Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. The Goldman Sachs Group cut their price objective on Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Barclays cut their price objective on Exact Sciences from $70.00 to $65.00 and set an “overweight” rating on the stock in a report on Thursday. Finally, Evercore ISI cut their price target on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Exact Sciences currently has an average rating of “Moderate Buy” and an average price target of $72.06.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.